Cardiac Sarcoidosis

详细信息    查看全文

• 作者：David H. Birnie ; MD ; MBChB^a ; ^{dbirnie@ottawaheart.ca" class="auth_mail" title="E-mail the corresponding author} ; Pablo B. Nery ; MD^a ; Andrew C. Ha ; MD^b ; Rob S.B. Beanlands ; MD^a
• 关键词：atrioventricular block ; clinically manifest ; clinically silent ; heart failure ; sudden cardiac death ; ventricular arrhythmias
• 刊名：Journal of the American College of Cardiology
• 出版年：2016
• 出版时间：26 July 2016
• 年：2016
• 卷：68
• 期：4
• 页码：411-421
• 全文大小：2284 K

文摘

Clinically manifest cardiac involvement occurs in perhaps 5% of patients with sarcoidosis. The 3 principal manifestations of cardiac sarcoidosis (CS) are conduction abnormalities, ventricular arrhythmias, and heart failure. An estimated 20% to 25% of patients with pulmonary/systemic sarcoidosis have asymptomatic cardiac involvement (clinically silent disease). In 2014, the first international guideline for the diagnosis and management of CS was published. In patients with clinically manifest CS, the extent of left ventricular dysfunction seems to be the most important predictor of prognosis. There is controversy in published reports as to the outcome of patients with clinically silent CS. Despite a paucity of data, immunosuppression therapy (primarily with corticosteroids) has been advocated for the treatment of clinically manifest CS. Device therapy, primarily with implantable cardioverter-defibrillators, is often recommended for patients with clinically manifest disease.